3,4,7-trimethylpyrazolo[5,1-c][1,2,4]triazine | 1113032-78-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并三嗪类
• 英文名称: 3,4,7-trimethylpyrazolo[5,1-c][1,2,4]triazine
• CAS: 1113032-78-2
• 化学式: C₈H₁₀N₄
• 分子量: 162.194
• InChiKey: GLQCJTIGIYWCLA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3,4,7-trimethylpyrazolo[5,1-c][1,2,4]triazine 、 乙酸酐 反应 1.0h， 以87%的产率得到1-{3,7-dimethyl-4-methylenepyrazolo[5,1-c][1,2,4]triazin-6(4H)-yl}ethanone
  参考文献：
  名称：

  10.3184/030823408x298887

  摘要：

  DOI：

  10.3184/030823408x298887
• 作为产物：
  描述：

  在 对甲苯磺酸 作用下， 以 乙醇 为溶剂， 反应 3.0h， 生成 3,4,7-trimethylpyrazolo[5,1-c][1,2,4]triazine
  参考文献：
  名称：

  10.3184/030823408x298887

  摘要：

  DOI：

  10.3184/030823408x298887

文献信息

• Compounds for Nonsense Suppression, and Methods for Their Use
  申请人：Almstead Neil G.

  公开号：US20090253699A1

  公开（公告）日：2009-10-08

  The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.

  本发明涉及使用本发明的化合物或组合物治疗或预防与mRNA中无意义突变相关的疾病的方法、化合物和组合物。更具体地，本发明涉及用于抑制与mRNA中无意义突变相关的早期翻译终止的方法、化合物和组合物。
• Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases
  申请人：PTC Therapeutics, Inc.

  公开号：EP2301536A1

  公开（公告）日：2011-03-30

  The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.

  本发明涉及通过施用本发明的化合物或组合物治疗或预防与 mRNA 中无义突变相关的疾病的方法、化合物和组合物。更具体地说，本发明涉及抑制与 mRNA 中无义突变相关的过早翻译终止的方法、化合物和组合物。
• Compounds for nonsense suppression, and methods for their use
  申请人：PTC Therapeutics, Inc.

  公开号：EP2301538A1

  公开（公告）日：2011-03-30

  The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.

  本发明涉及通过施用本发明的化合物或组合物治疗或预防与 mRNA 中无义突变相关的疾病的方法、化合物和组合物。更具体地说，本发明涉及抑制与 mRNA 中无义突变相关的过早翻译终止的方法、化合物和组合物。
• COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE
  申请人：PTC Therapeutics, Inc.

  公开号：EP2939674A1

  公开（公告）日：2015-11-04

  The present invention relates to methods of Formula (1-A) , and such compounds for use in the treatment or prevention of diseases associated with nonsense mutations in an mRNA, such as for suppressing premature translation termination associated with a nonsense mutation in an mRNA.

  本发明涉及式（1-A）的方法 及此类化合物，用于治疗或预防与 mRNA 中无义突变相关的疾病，例如抑制与 mRNA 中无义突变相关的过早翻译终止。
• US9611230B2
  申请人：——

  公开号：US9611230B2

  公开（公告）日：2017-04-04